CDK4/6 Inhibitor Therapy

CDK4/6 inhibitor therapy uses targeted tablets to slow cancer-cell division, usually alongside hormone therapy.

These medicines interrupt proteins that help some cancer cells move through the cell cycle. They are commonly considered for hormone receptor-positive breast cancer, where hormone treatment remains an important partner. The exact medicine and hormone treatment depend on whether cancer is early, locally advanced or has spread, previous treatment, menopausal status and other health conditions.

Treatment is taken by mouth on a schedule set by the oncology team. Some medicines are taken daily without a break, while others include planned days off. You will receive instructions about the dose, missed tablets, food interactions and medicines or supplements to avoid. Blood tests and review appointments help the team decide whether the schedule remains suitable.

Tiredness, nausea, diarrhoea, reduced appetite, mouth soreness and changes in blood counts can occur. Some CDK4/6 inhibitors can lower infection-fighting white cells; a fever, chills, feeling suddenly unwell, shortness of breath, new chest pain, yellowing of the skin or eyes, or severe diarrhoea needs prompt clinical advice. Do not wait for a routine visit if these symptoms appear.

The aim may be to reduce the chance of cancer returning after other treatment, to control cancer that cannot be removed, or to manage cancer that has spread. Response is assessed using your symptoms, examination, blood tests and scans when appropriate. Benefit varies with the cancer setting and tumour features, so your clinician can explain what the planned treatment is intended to achieve for you.

Targeted treatment still needs careful monitoring. Tell the team about heart, liver or lung problems, pregnancy plans, all prescriptions, over-the-counter products and herbal remedies. Keep a current medicines list and use the contact number supplied by your treatment unit for new symptoms.

An oncology team may discuss this option with people whose breast cancer has hormone receptors and whose treatment plan calls for systemic therapy. It is not the same plan for every person with that diagnosis. The pathology report, stage, prior medicines, organ function and potential interactions all influence whether a CDK4/6 inhibitor is appropriate.

Before treatment, the team reviews pathology, medical history and current medicines, then arranges baseline tests. During treatment, take tablets as directed and report symptoms between visits. Clinicians may continue, pause, reduce or change a dose according to blood results, side effects and how the cancer is responding.

There is no surgical recovery period, but it can take time to establish a routine with regular tablets and monitoring. Keep appointments even if you feel well. If side effects affect work, sleep, eating or daily activities, the team can consider supportive care or a treatment adjustment.

The main safety issue is recognising symptoms that need rapid review, particularly signs of infection or breathing difficulty. Blood tests can detect changes before they cause symptoms. Never share tablets, double a dose after a missed dose, or stop treatment without discussing it with the prescribing team unless you have been told to do so in an emergency plan.

Depending on the cancer situation, alternatives or companion treatments may include hormone therapy alone, other targeted medicines, chemotherapy, radiotherapy or surgery. Some plans use treatments in sequence. A decision is based on the biology of the cancer and the balance between expected benefit, side effects and your preferences.

Seek care from an oncology service that can provide prescribing, blood-test monitoring and advice between appointments. Bring your pathology information and medicines list. A pharmacist can also help check interactions and explain safe tablet storage.